Abstract:Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD, is a leading cause of chronic liver disease worldwide. Current diagnostic methods, including liver biopsies, are invasive and have significant limitations, emphasizing the need for non-invasive alternatives. This study aimed to evaluate extracellular vesicles (EV) as biomarkers for diagnosing and staging steatosis in MASLD patients, utilizing machine learning (ML) and explainable artificial intelligence (XAI). Methods: This prospective, single-center cohort study was conducted at the GI-Liver Unit, Hippocration General Hospital, Athens. It included 76 MASLD patients with ultrasound-confirmed steatosis and at least one cardiometabolic risk factor. Patients underwent transient elastography for steatosis and fibrosis staging and blood sampling for EV analysis using nanoparticle tracking. Twenty machine learning models were developed. Six to distinguish non-steatosis (S0) from steatosis (S1-S3), and fourteen to identify severe steatosis (S3). Models incorporated EV measurements (size and concentration), anthropomorphic and clinical features, with performance evaluated using AUROC and SHAP-based interpretability methods. Results: The CB-C1a model achieved, on average on 10 random splits of 5-fold cross validation (5CV) of the train set, an AUROC of 0.71/0.86 (train/test) for distinguishing S0 from S1-S3 steatosis stages, relying on EV alone. The CB-C2h-21 model identified severe steatosis (S3), on average on 10 random splits of 3-fold cross validation (3CV) of the train set, with an AUROC of 0.81/1.00 (train/test), demonstrating superior performance when combining EV with anthropomorphic and clinical features such as diabetes and advanced fibrosis. Key EV features, including mean size and concentration, were identified as important predictors. SHAP analysis highlighted complex non-linear relationships between features and steatosis staging. Conclusions: EV are promising non-invasive biomarkers for diagnosing and staging MASLD. The integration of ML-enhanced EV analysis with clinical features offers a scalable, patient-friendly alternative to invasive liver biopsies, advancing precision in MASLD management. Further research should refine these methods for broader clinical application. Keywords: Metabolic dysfunction-associated steatotic liver disease (MASLD), extracellular vesicles (EVs), non-invasive biomarkers, machine learning (ML), explainable artificial intelligence (XAI), steatosis staging, transient elastography, chronic liver disease, cardiometabolic risk factors, SHAP analysis, diagnostic precision, advanced fibrosis, severe steatosis (S3), liver biopsy alternatives, hepatology diagnostics.

A Lipidomics-Driven Machine Learning Approach

Lipoprotein Lipidomics as a Frontier in Non-Alcoholic Fatty Liver Disease Biomarker Discovery

Application of Machine Learning Techniques for Clinical Predictive Modeling: A Cross-Sectional Study on Nonalcoholic Fatty Liver Disease in China

Machine Learning Reveals Serum Glycopatterns as Potential Biomarkers for the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD)

Machine Learning Reveals the Contribution of Lipoproteins to Liver Triglyceride Content and Inflammation

Machine Learning to Predict Progression of Non‐alcoholic Fatty Liver to Non‐alcoholic Steatohepatitis or Fibrosis

Machine learning approaches for early detection of non-alcoholic steatohepatitis based on clinical and blood parameters

Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease

Automated machine learning models for nonalcoholic fatty liver disease assessed by controlled attenuation parameter from the NHANES 2017-2020

High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease

Development and validation of machine learning models for nonalcoholic fatty liver disease

LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver

Extracellular Vesicles as Biomarkers for Steatosis Stages in MASLD Patients: an Algorithmic Approach Using Explainable Artificial Intelligence

A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease.

1567-P: Integrating Bioinformatics and Machine Learning to Identify Lactylation-Related Diagnostic Biomarkers and Characterize Immune Cell Infiltration in Nonalcoholic Fatty Liver Disease

Lipidomic-Based Algorithms Can Enhance Prediction of Obstructive Coronary Artery Disease

Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests

Comparison and development of advanced machine learning tools to predict nonalcoholic fatty liver disease: An extended study

Integration of metabolomics, lipidomics and clinical data using a machine learning method

A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures

Untargeted Profiling of Bile Acids and Lysophospholipids Identifies the Lipid Signature Associated with Glycemic Outcome in an Obese Non-Diabetic Clinical Cohort